VDR and ovarian cancer: Of note is the use of 1,25-dihydroxyvitamin D3 (1,25D), the biologically active form of vitamin D which activates the vitamin D receptor (VDR), which has been reported to abrogate a stemness phenotype in ovarian cancer cells [55].